Schonfeld Strategic Advisors Reduces $521K in ANI Pharmaceuticals, Inc. ($ANIP)
Key Points
- Schonfeld Strategic Advisors changed its ANI Pharmaceuticals, Inc. ($ANIP) stake by 3.3% last quarter, cutting to 185,629 shares worth $15.16 million.
- Wall Street's consensus rating on $ANIP is Strong Buy and an average price target of $112.71.
- $ANIP last traded around $81.68.
Schonfeld Strategic Advisors trimmed its position in ANI Pharmaceuticals, Inc. ($ANIP) by 3.3% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 185,629 shares of ANI Pharmaceuticals, Inc. after selling 6,377 shares during the quarter. Schonfeld Strategic Advisors's holdings in ANI Pharmaceuticals, Inc. were worth $15.16 million as of its most recent filing.
ANI Pharmaceuticals, Inc. ($ANIP) Stock
ANI Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.